Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | EVP, R&D & Chief Scientific Of | February 15, 2019 | February 19, 2019 |
| Elicio Therapeutics, Inc.ELTX · Entity 299 | See Remarks | July 16, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date February 15, 2019 · Filed February 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 271,943 |
Reported balance
After 2019-02-15 transaction · row 1
1 source rowRow 1 · 2019-02-15 · Sale · Disposed 775 · Balance 271,943 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.33 to $39.695. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 17,312 |
Reported balance
Holding disclosure · report date 2019-02-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 17,312 F3: The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,688 |
Reported balance
Holding disclosure · report date 2019-02-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,688 F4: The shares are held by The Havenside Trust, of which the Reporting Person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018.
F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.33 to $39.695. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee.
F4: The shares are held by The Havenside Trust, of which the Reporting Person is trustee.
Elicio Therapeutics, Inc.
Report date July 16, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2036-07-16 | Direct | 64,643 |
Reported balance
After 2026-07-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-16 · Grant · Acquired 64,643 · Balance 64,643 F1: The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Surrozen, Inc./DE
Report date August 11, 2021 · Filed August 13, 2021
Section 16 reporting ended · disclosed 2021-08-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2021-08-11 transaction · row 1
1 source rowRow 1 · 2021-08-11 · Grant · Acquired 30,000 · Balance 30,000 F1: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", F2: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination". |
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-08-11 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", F2: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination". |
Filing footnotes · ownership attribution and instrument terms
F1: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.",
F2: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2017 Filed Feb 17, 2017 01:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 829 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011764 · doc4.xml · derivative · entry 5 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,040 Underlying: Common Stock · 829 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F7 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date. F8 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 01:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,604 | $15.49 | $117,785.96 |
DisclosureSEC source: 0001209191-17-011764 · doc4.xml · nonDerivative · entry 2 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,855 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted December 7, 2015. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.30 to $15.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 01:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 829 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011764 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| February 09, 2017 Filed Feb 10, 2017 23:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 13,975 | $15.46 | $216,053.50 |
DisclosureSEC source: 0001209191-17-009718 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,630 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.15 to $15.90. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 22:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 49,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008830 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,605 F1 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 00:52 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,000 | $14.27 | $85,620.00 |
DisclosureSEC source: 0001209191-17-004333 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,105 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.00 to $14.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 15, 2016 Filed Dec 16, 2016 00:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,000 | $15.40 | $92,400.00 |
DisclosureSEC source: 0001209191-16-155509 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,105 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 23:40 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,068 | $17.85 | $126,163.80 |
DisclosureSEC source: 0001209191-16-151797 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,105 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:53 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 829 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150914 · doc4.xml · derivative · entry 5 Haqq Christopher · CIK 0001612095 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,869 Underlying: Common Stock · 829 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F7 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date. F8 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:53 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,604 | $19.95 | $31,999.80 |
DisclosureSEC source: 0001209191-16-150914 · doc4.xml · nonDerivative · entry 2 Haqq Christopher · CIK 0001612095 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,173 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted December 7, 2015. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $19.55 to $20.30. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:53 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 829 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150914 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| September 22, 2016 Filed Sep 23, 2016 23:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142708 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,948 F1 · shares: These restricted stock units vest over 4 years, 50% on the 2nd anniversary of the grant date of September 22, 2016 and 25% on the anniversary of the grant date of September 22, 2016 in each of the following years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.